医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters

2019年09月10日 PM11:52
このエントリーをはてなブックマークに追加


 

BETHLEHEM, Pa.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced the availability of Custom Single Run (CSR®) Bioreactors with working volumes up to 6,000L. The 6,000L volume increases ABEC’s industry-leading 4,000L volume while continuing to deliver performance comparable to stainless steel systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005787/en/

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters (Graphic: Business Wire)

ABEC Advances Single-Use Bioreactor Volumes to 6,000 Liters (Graphic: Business Wire)

ABEC remains the only supplier providing fully-customizable single-use bioreactors with large scale capacity. The 6,000L CSR Bioreactor increases cell culture capacity per unit of floorspace, resulting in significant savings in capital, facility, and disposables cost. CSR bioreactor geometries are aligned with decades of industry experience scaling in stainless steel, delivering equivalent power per volume while maintaining low shear mixing. Consistent with all CSR products, the material, instrument, and component supply chains remain fully-transparent and non-proprietary so that biopharmaceutical manufacturers have better control and flexibility to manage quality, cost, and regulatory compliance.

“We understand that our customers cannot compromise on scalability and cost of goods when realizing other single-use benefits such as multi-product flexibility,” said Scott Pickering, ABEC President and CEO. “In applications where single-use is preferred, with 6,000L CSR bioreactors, customers can now achieve even greater economies of scale for cell culture production.”

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a customized, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. www.abec.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005787/en/

CONTACT

Media Contact:

ABEC

Susan Cooper Curcio

+1 (610) 861 4666

scurcio@abec.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作